Download our whitepaper,
Alzheimer’s Clinical Trials: From
Diagnosis to Disease Progression
Optimization
What's Inside:
- Overview of Alzheimer’s disease diagnosis and staging.
- Cognitive and functional assessment tools (ADAS-Cog, CDR-SB).
- Use of amyloid and tau biomarkers in clinical trials.
- Emerging imaging techniques and neurodegeneration monitoring.
- Innovative designs for early-stage and disease-modifying therapies.
- Challenges in patient recruitment and caregiver engagement.
Access your complimentary whitepaper today:
Alzheimer’s Disease
Alzheimer’s Disease is a progressive neurological disorder that primarily affects memory, thinking, and behavior. Over time, it leads to cognitive decline, confusion, and loss of independence, ultimately requiring long-term care and support.
Once regarded as a purely cognitive condition, research has revealed that Alzheimer’s involves a complex interaction of genetic, neurobiological, and environmental factors. This growing understanding has paved the way for the development of therapies that not only address symptoms but also target the underlying mechanisms driving the disease.
At iNGENū, our team of expert researchers and clinicians is deeply committed to advancing Alzheimer’s research. Through innovative clinical trial designs and a patient-centered approach, we strive to accelerate the development of next-generation treatments that aim to improve the quality of life for those affected by Alzheimer’s Disease.
6th
leading cause of death in the United States
2x
more common in women than in men
4 Million
people under 65 live with early-onset Alzheimer’s Disease
Our clinical team has over
120
years of combined clinical trial experience